Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAV Regimen for R/R Ph- B-ALL
NCT05657652Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax, cladribine and cytarabine in acute lymphoblastic leukemia (ALL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall Response Rate at 21 days. Started Oct 2022; status: recruiting.
02
Drugs
venetoclaxcladribinecytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05657652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657652.